Product Images Praluent

View Photos of Packaging, Labels & Appearance

Figure 1 - s praluent 01
Figure 2 - s praluent 02
Figure 3 - s praluent 03
Figure 4 - s praluent 03a
s praluent 03b
Figure - s praluent 04
Figure - s praluent 05
Figure - s praluent 06
Figure - s praluent 07
Figure - s praluent 08
Picture A - s praluent 09
Figure B - s praluent 10
Figure - s praluent 11
Figure - s praluent 12
Figure - s praluent 13
Figure - s praluent 14
Figure - s praluent 15
Figure - s praluent 16
Figure - s praluent 17
Figure - s praluent 18
Figure - s praluent 19
Figure - s praluent 20
Figure - s praluent 21
Figure - s praluent 22
Picture A - s praluent 23
Figure B - s praluent 24
Figure - s praluent 25
Figure - s praluent 26
Figure - s praluent 27
Figure - s praluent 28
Figure - s praluent 29
Figure - s praluent 30
Figure - s praluent 31
PRINCIPAL DISPLAY PANEL - 75 mg/mL Pen Carton - s praluent 54
PRINCIPAL DISPLAY PANEL - 150 mg/mL Pen Carton - s praluent 55

Product Label Images

The following 35 images provide visual information about the product associated with Praluent NDC 61755-020 by Regeneron Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - s praluent 01

Figure 2 - s praluent 02

This looks like a graph/chart that illustrates the mean percent change in LDL-C from baseline over time for two groups of individuals receiving different treatments. The two groups are labeled "PRALUENT" and "Placebo." The x-axis shows time in weeks, and the y-axis shows the percent change in LDL-C. The graph shows that PRALUENT had a greater reduction in LDL-C compared to Placebo over the course of the study.*

Figure 3 - s praluent 03

The text seems to be a graph with two lines representing the mean percent change in LDL-C (a type of cholesterol) from baseline at different time points (weeks) for two treatments: Placebo and PRALUENT. The x-axis shows the time points in weeks and the y-axis shows the mean percent change from baseline. The PRALUENT line appears to decrease more rapidly than the Placebo line, indicating that PRALUENT is more effective at reducing LDL-C levels over time.*

Figure 4 - s praluent 03a

This is a chart showing the LDL-C LS mean percent change from baseline over time points in weeks. The chart includes data for a placebo group, a Praluent75 Q2W group, and a Praluent 300 Q4W group. The x-axis represents the time points (in weeks), and the y-axis represents the percent change from baseline.*

s praluent 03b

This is a table showing the mean percent change from baseline of LDL-C levels at different time points (4, 8, and 12 weeks) for a group of 45 patients treated with PRALUENT 150 mg Q2W and a group of 24 patients treated with a placebo.*

Figure - s praluent 04

This description is not sufficient to generate a useful description.*

Figure - s praluent 05

Figure - s praluent 06

Figure - s praluent 07

Figure - s praluent 08

Picture A - s praluent 09

Figure B - s praluent 10

Figure - s praluent 11

Figure - s praluent 12

Figure - s praluent 13

Figure - s praluent 14

Figure - s praluent 15

Figure - s praluent 16

Figure - s praluent 17

Figure - s praluent 18

Figure - s praluent 19

Figure - s praluent 20

Figure - s praluent 21

Figure - s praluent 22

Picture A - s praluent 23

Figure B - s praluent 24

This text is not available as it only contains non-English characters and a few symbols.*

Figure - s praluent 25

Figure - s praluent 26

Figure - s praluent 27

This is a prompt or command that instructs someone to release a button right away.*

Figure - s praluent 28

Figure - s praluent 29

Figure - s praluent 30

Figure - s praluent 31

PRINCIPAL DISPLAY PANEL - 75 mg/mL Pen Carton - s praluent 54

Praluent is a medication that is available in the form of an injection. Each pre-filled pen of Praluent contains 75mg alirocumab and is intended for single-dose, subcutaneous injection. In addition to alirocumab, the pen contains histidine, polysorbate 20, sucrose, and water. Caution must be taken to keep Praluent out of reach of children and to avoid use if the seal is broken or the package is damaged. Patients should consult the package insert for dosage information and administration instructions. Praluent must be kept refrigerated between 2°C to 8°C, with proper protection from light, and should not be frozen or exposed to extreme temperatures or shaken. If necessary, the medication can be stored at room temperature up to 77°F (25°C) for a maximum of 30 days. Once removed from the refrigerator, Praluent must be used within 30 days.*

PRINCIPAL DISPLAY PANEL - 150 mg/mL Pen Carton - s praluent 55

This text is a description of the drug Praluent (alirocumab) that comes in a prefilled pen for subcutaneous injection only. Each pen contains 150mg of the drug and the ingredients include histidine, polysorbate 20, sucrose, and water for injection. The drug must be stored in a refrigerator and not be frozen, exposed to extreme heat or light, or shaken. If the package is damaged, do not use it. The drug should be used within 30 days after removal from the refrigerator. The text also includes some identification codes for the drug.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.

Table of Contents